You are viewing just a glimpse of the 100+ pieces of sophisticated insight and analysis produced by our full-time team of senior financial journalists every day. For full access, check to see if your firm has a license to The Deal Pipeline or login using your existing credentials.
Published November 25, 2009 at 2:52 PM
Abbott Laboratories (NYSE:ABT) for the second straight year took home the Most Admired Corporate Dealmaker award in the pharma-biotech category. The pharmaceutical firm has executed $30 billion in transactions in the past decade, $10 billion of that coming since January, including the $6.6 billion cash acquisition of Solvay Pharmaceuticals SA in September. Sean Murphy, vice president for new business development, says Abbott will remain active in 2010, but he expects overall deal active in the industry to slow. See the video below or
download it at iTunes. - Suzanne Stevens
Leezie Kim is rejoining the Phoenix office of Quarles & Brady LLP as a partner. She will continue her corporate transactions practice. For other updates launch today's Movers & shakers slideshow.
Dechert's Henry Nassau at the 18th annual Wharton Private Equity and Venture Capital Conference tells The Deal Pipeline how to shine in the middle market. More video
Search
